Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EPRX Eupraxia Pharmaceuticals

Post-Mkt 12-22 17:44:39 EST

7.00

+0.44

+6.71%

盘后7.00

+0.000.00%

16:10 EST

High7.37	Low6.41	Vol437.09K
Open6.58	D1 Closing6.56	Amplitude14.71%
Mkt Cap354.54M	Tradable Cap277.40M	Total Shares50.65M
T/O3.07M	T/O Rate1.10%	Tradable Shares39.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EPRX","market":"US","secType":"STK","nameCN":"Eupraxia Pharmaceuticals","latestPrice":7,"timestamp":1766437200000,"preClose":6.56,"halted":0,"volume":437090,"hourTrading":{"tag":"盘后","latestPrice":7,"preClose":7,"latestTime":"16:10 EST","volume":96,"amount":672,"timestamp":1766437803828},"delay":0,"floatShares":39629000,"shares":50648331,"eps":-0.879812,"marketStatus":"Post-Mkt","change":0.44,"latestTime":"12-22 17:44:39 EST","open":6.58,"high":7.37,"low":6.405,"amount":3070045.9688,"amplitude":0.147104,"askPrice":8.68,"askSize":100,"bidPrice":6.41,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.879812,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766451600000},"marketStatusCode":4,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":6.56,"preHourTrading":{"tag":"盘前","latestPrice":6.7,"preClose":6.56,"latestTime":"09:29 EST","volume":31,"amount":206.49999,"timestamp":1766413770065},"postHourTrading":{"tag":"盘后","latestPrice":7,"preClose":7,"latestTime":"16:10 EST","volume":96,"amount":672,"timestamp":1766437803828},"volumeRatio":2.690341},"requestUrl":"/m/hq/s/EPRX","defaultTab":"news","newsList":[{"id":"2582804472","title":"Eupraxia Pharmaceuticals Up Nearly 16%, on Pace for Largest Percent Increase Since November 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2582804472","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582804472?lang=en_us&edition=fundamental","pubTime":"2025-11-11 03:30","pubTimestamp":1762803000,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals, Inc.  is currently at $6.31, up $0.86 or 15.78%. --Would be highest close since Sept. 22, 2025, when it closed at $6.65. --On pace for largest percent increase since Nov. 1, 2024, when it rose 28.36%. --Up 99.05% year-to-date; on pace for best year on record . --Down 6.88% from its all-time closing high of $6.78 on July 6, 2023. --Up 109.63% from 52 weeks ago , when it closed at $3.01. --Traded as high as $6.32; highest intraday level since Sept. 23, 2025, when it hit $6.41","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2581675747","title":"Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581675747","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581675747?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:43","pubTimestamp":1762292613,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48639239/eupraxia-pharmaceuticals-q3-eps-0-19-beats-0-21-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"gpt_icon":0},{"id":"2581767111","title":"Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581767111","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581767111?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:39","pubTimestamp":1762292340,"startTime":"0","endTime":"0","summary":"Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180937/0/en/Eupraxia-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2581762090","title":"Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581762090","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581762090?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:33","pubTimestamp":1762292015,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an update. Eupraxia Pharmaceuticals Inc. released its consolidated financial statements and man...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-releases-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-releases-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2578620112","title":"Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2578620112","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578620112?lang=en_us&edition=fundamental","pubTime":"2025-10-28 03:38","pubTimestamp":1761593885,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals, Inc. (($TSE:EPRX)) announced an update on their ongoing clinical study. Study Overview: Eupraxia Pharmaceuticals, Inc. is...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-advances-eoe-treatment-with-ep-104gi-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-advances-eoe-treatment-with-ep-104gi-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4213","BK4139","EPRX","EP"],"gpt_icon":0},{"id":"2572558958","title":"Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2572558958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572558958?lang=en_us&edition=fundamental","pubTime":"2025-10-01 23:18","pubTimestamp":1759331901,"startTime":"0","endTime":"0","summary":"An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. On September 29, 2025, Eupraxia Pharmaceuticals announced positive data f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-positive-results-in-eoe-trial-and-plans-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-positive-results-in-eoe-trial-and-plans-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2571032258","title":"Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2571032258","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571032258?lang=en_us&edition=fundamental","pubTime":"2025-09-30 23:35","pubTimestamp":1759246535,"startTime":"0","endTime":"0","summary":"In a report released today, from Raymond James reiterated a Buy rating on Eupraxia Pharmaceuticals, with a price target of $12.00. The company’s sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/raymond-james-sticks-to-their-buy-rating-for-eupraxia-pharmaceuticals-eprx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/raymond-james-sticks-to-their-buy-rating-for-eupraxia-pharmaceuticals-eprx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","RJF"],"gpt_icon":0},{"id":"2571936370","title":"Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2571936370","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571936370?lang=en_us&edition=fundamental","pubTime":"2025-09-30 05:06","pubTimestamp":1759179964,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an update. On September 24, 2025, Eupraxia Pharmaceuticals Inc. announced the successful clos...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-closes-80-5-million-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-closes-80-5-million-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2571363471","title":"Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2571363471","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571363471?lang=en_us&edition=fundamental","pubTime":"2025-09-30 05:00","pubTimestamp":1759179600,"startTime":"0","endTime":"0","summary":"Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3158170/0/en/Eupraxia-Pharmaceuticals-Announces-Positive-Data-from-Highest-Dose-Cohort-in-the-Ongoing-RESOLVE-Trial-in-Eosinophilic-Esophagitis-and-Plans-for-Expansion-of-EP-104GI-Development-P.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139","BK4213","EP"],"gpt_icon":0},{"id":"2569702683","title":"Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2569702683","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569702683?lang=en_us&edition=fundamental","pubTime":"2025-09-24 21:24","pubTimestamp":1758720297,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals  said Wednesday that it has closed its public offering of about 14.6 million common shares priced at $5.50 per share, with the underwriters fully exercising an option to buy additional shares.The company said it raised about $80.5 million in gross proceeds. Net proceeds will be used for further development of its product pipeline, research and development of additional pipeline candidates, business development activities, and general corporate purposes, the company added.Shares of Eupraxia Pharmaceuticals were up more than 12% in recent Wednesday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2569148712","title":"Eupraxia Pharmaceuticals Down Over 7%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2569148712","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569148712?lang=en_us&edition=fundamental","pubTime":"2025-09-24 00:44","pubTimestamp":1758645840,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals, Inc.  is currently at C$8.19, down C$0.68 or 7.67%. --On pace for largest percent decrease since March 12, 2024, when it fell 33.33%. --Up 10.38% month-to-date; on pace for best month since June 2025, when it rose 46.82%. --Down 7.98% from its all-time closing high of C$8.90 on July 7, 2023. --Up 121.35% from 52 weeks ago , when it closed at C$3.70. --Down 10.03% at today's intraday low; largest intraday percent decrease since July 21, 2025, when it fell as much as 10.97%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2569711754","title":"Eupraxia Pharmaceuticals Prices $70 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2569711754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569711754?lang=en_us&edition=fundamental","pubTime":"2025-09-23 23:27","pubTimestamp":1758641237,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an announcement. On September 22, 2025, Eupraxia Pharmaceuticals announced the pricing of a pub...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-prices-70-million-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-prices-70-million-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2569799078","title":"Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2569799078","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569799078?lang=en_us&edition=fundamental","pubTime":"2025-09-23 18:20","pubTimestamp":1758622828,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald and LifeSci Capital acted as joint book running managers for the offering. Published first on TheFly – the ultimate source for re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-12-727m-share-spot-secondary-priced-at-5-50-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-12-727m-share-spot-secondary-priced-at-5-50-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2569730181","title":"Eupraxia Pharmaceuticals Proposes Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2569730181","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569730181?lang=en_us&edition=fundamental","pubTime":"2025-09-23 04:24","pubTimestamp":1758572640,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals  said late Monday it has filed a preliminary prospectus supplement to its short form base shelf prospectus for a public offering of shares.The firm expects to grant its underwriters a 30-day option to buy up to an additional 15% of shares offered in the offering.Shares were over 2% lower in after-market activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2569073092","title":"Eupraxia Pharmaceuticals announces common shares offering, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2569073092","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569073092?lang=en_us&edition=fundamental","pubTime":"2025-09-23 04:10","pubTimestamp":1758571838,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (EPRX) has filed a preliminary prospectus supplement to its short form base shelf prospectus dated February 5, 2024 in con...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-announces-common-shares-offering-no-amount-given-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-announces-common-shares-offering-no-amount-given-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2569212730","title":"Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2569212730","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569212730?lang=en_us&edition=fundamental","pubTime":"2025-09-23 04:01","pubTimestamp":1758571260,"startTime":"0","endTime":"0","summary":"VICTORIA, British Columbia, Sept.  22, 2025  (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc.(“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3154291/0/en/Eupraxia-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2568729991","title":"Eupraxia Pharmaceuticals Appoints New CFO Amid Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2568729991","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568729991?lang=en_us&edition=fundamental","pubTime":"2025-09-20 04:17","pubTimestamp":1758313031,"startTime":"0","endTime":"0","summary":"An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. On February 18, 2025, Eupraxia Pharmaceuticals announced the appointment ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-appoints-new-cfo-amid-leadership-transition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-appoints-new-cfo-amid-leadership-transition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2564040818","title":"First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI","url":"https://stock-news.laohu8.com/highlight/detail?id=2564040818","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564040818?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:00","pubTimestamp":1756814400,"startTime":"0","endTime":"0","summary":"At 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GIAll Cohorts followed to 9 months have maintained clinically meanin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/02/3142594/0/en/First-Set-of-1-Year-Clinical-Results-from-RESOLVE-Trial-in-Eosinophilic-Esophagitis-EoE-Durable-and-Sustained-Symptom-Tissue-Responses-after-Dosing-with-EP-104GI.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139","BK4213","EP"],"gpt_icon":0},{"id":"2560917223","title":"Eupraxia Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2560917223","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560917223?lang=en_us&edition=fundamental","pubTime":"2025-08-20 18:42","pubTimestamp":1755686520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 20, 2025 06:42 ET (10:42 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"gpt_icon":0},{"id":"2559162226","title":"Eupraxia Pharmaceuticals Q2 EPS $(0.26) Misses $(0.19) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559162226","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559162226?lang=en_us&edition=fundamental","pubTime":"2025-08-13 06:03","pubTimestamp":1755036207,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.19) by 36.84 percent. This is a 52.94 percent decrease over losses of $(0.17) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47078008/eupraxia-pharmaceuticals-q2-eps-0-26-misses-0-19-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Eupraxia Pharmaceuticals Q2 EPS $(0.26) Misses $(0.19) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eupraxiapharma.com","stockEarnings":[{"period":"1week","weight":0.0463},{"period":"1month","weight":0.0581},{"period":"3month","weight":0.1007},{"period":"6month","weight":0.5185},{"period":"1year","weight":1.1867},{"period":"ytd","weight":1.0694}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.","exchange":"NASDAQ","name":"Eupraxia Pharmaceuticals","nameEN":"Eupraxia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eupraxia Pharmaceuticals(EPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eupraxia Pharmaceuticals,EPRX,Eupraxia Pharmaceuticals股票,Eupraxia Pharmaceuticals股票老虎,Eupraxia Pharmaceuticals股票老虎国际,Eupraxia Pharmaceuticals行情,Eupraxia Pharmaceuticals股票行情,Eupraxia Pharmaceuticals股价,Eupraxia Pharmaceuticals股市,Eupraxia Pharmaceuticals股票价格,Eupraxia Pharmaceuticals股票交易,Eupraxia Pharmaceuticals股票购买,Eupraxia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eupraxia Pharmaceuticals(EPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction